Mouse models of experimental atherosclerosis.

Since 1992 the mouse has become an excellent model for experimental atherosclerosis research. Until 1992, the diet -- induced atherosclerosis mouse model has been used effectively, but the lesions tended to be small and were limited to early fatty-streak stage. This model was also criticized because of the toxicity and inflammatory responses due to the diet. In 1992 the first line of gene targeted animal models, namely apolipoprotein E -- knockout mice was developed. Of the genetically engineered models, the apoE -- deficient model is the only one that develops extensive atherosclerotic lesions on a chow diet. It is also the model in which the lesions have been characterized most thoroughly. The lesions develop into fibrous plaques; however, there is no evidence that plaque rupture occurs in this model. The LDL receptor - deficient model has elevated LDL levels, but no lesions, or only very small lesions, form on the chow diet, however, robust lesions do form on the western-type diet. The creation of apoE -- knockout mice has changed the face of atherosclerosis research.

[1]  Robert V Farese,et al.  Transgenic mice expressing high levels of human apolipoprotein B develop severe atherosclerotic lesions in response to a high-fat diet. , 1995, The Journal of clinical investigation.

[2]  R. Ross Atherosclerosis is an inflammatory disease , 1999 .

[3]  D. Steinberg,et al.  Effect of the antioxidant N,N'-diphenyl 1,4-phenylenediamine (DPPD) on atherosclerosis in apoE-deficient mice. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[4]  B. Paigen,et al.  Variation in susceptibility to atherosclerosis among inbred strains of mice. , 1985, Atherosclerosis.

[5]  R. Coleman,et al.  The angiotensin-converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoprotein E deficient mice. , 1999, Cardiovascular research.

[6]  R. Stocker,et al.  Inhibition by a coantioxidant of aortic lipoprotein lipid peroxidation and atherosclerosis in apolipoprotein E and low density lipoprotein receptor gene double knockout mice , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[7]  A. Gown,et al.  Fatty streak expansion and maturation in Watanabe Heritable Hyperlipemic and comparably hypercholesterolemic fat-fed rabbits. , 1987, Arteriosclerosis.

[8]  K. Channon,et al.  Mechanisms of superoxide production in human blood vessels: relationship to endothelial dysfunction, clinical and genetic risk factors. , 2002, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[9]  R. Coleman,et al.  Attenuation of atherosclerosis in apolipoprotein E-deficient mice by ramipril is dissociated from its antihypertensive effect and from potentiation of bradykinin. , 2000, Journal of cardiovascular pharmacology.

[10]  L. Ignarro,et al.  Nitric oxide as a unique signaling molecule in the vascular system: a historical overview. , 2002, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[11]  J. Breslow,et al.  Antiatherosclerotic and antioxidative effects of captopril in apolipoprotein E-deficient mice. , 1998, Journal of cardiovascular pharmacology.

[12]  R. Ross,et al.  Studies of Hypercholesterolemia in the Nonhuman Primate: II. Fatty Streak Conversion to Fibrous Plaque , 1984, Arteriosclerosis.

[13]  B. Malinowska,et al.  Function of nociceptin and opioid OP4 receptors in the regulation of the cardiovascular system. , 2002, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[14]  D. Heistad,et al.  Atherosclerosis, vascular remodeling, and impairment of endothelium-dependent relaxation in genetically altered hyperlipidemic mice. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[15]  S. Fazio,et al.  Type III hyperlipoproteinemic phenotype in transgenic mice expressing dysfunctional apolipoprotein E. , 1993, The Journal of clinical investigation.

[16]  Colin N. Dewey,et al.  Initial sequencing and comparative analysis of the mouse genome. , 2002 .

[17]  S. Young,et al.  Lipoprotein size and atherosclerosis susceptibility in Apoe(-/-) and Ldlr(-/-) mice. , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[18]  B. Wieringa,et al.  Diet-induced hypercholesterolemia and atherosclerosis in heterozygous apolipoprotein E-deficient mice. , 1994, Atherosclerosis.

[19]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[20]  N. Maeda,et al.  Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. , 1992, Science.

[21]  R. Williams,et al.  Quantitative assessment of atherosclerotic lesions in mice. , 1987, Atherosclerosis.

[22]  E. Rubin,et al.  Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells , 1992, Cell.

[23]  N. Maeda,et al.  Atherosclerosis in mice lacking apo E. Evaluation of lesional development and progression. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[24]  N. Maeda,et al.  Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[25]  P. de Knijff,et al.  Familial dysbetalipoproteinemia associated with apolipoprotein E3-Leiden in an extended multigeneration pedigree. , 1991, The Journal of clinical investigation.

[26]  V. Ord,et al.  ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis. Demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[27]  J. Breslow Lipoprotein metabolism and atherosclerosis susceptibility in transgenic mice. , 1994, Current opinion in lipidology.

[28]  J. Breslow,et al.  Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[29]  R. Hammer,et al.  Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. , 1993, The Journal of clinical investigation.

[30]  H. Brewer,et al.  Apolipoprotein E deficiency in mice: gene replacement and prevention of atherosclerosis using adenovirus vectors. , 1995, The Journal of clinical investigation.

[31]  B. McManus,et al.  Proatherogenic and antiatherogenic effects of probucol and phytosterols in apolipoprotein E-deficient mice: possible mechanisms of action. , 1999, Circulation.

[32]  Paul L Huang,et al.  Accelerated Atherosclerosis, Aortic Aneurysm Formation, and Ischemic Heart Disease in Apolipoprotein E/Endothelial Nitric Oxide Synthase Double-Knockout Mice , 2001, Circulation.

[33]  D. Rader,et al.  Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in ApoE-deficient mice , 1998, Nature Medicine.

[34]  D. Steinberg,et al.  Effect of probucol on LDL oxidation and atherosclerosis in LDL receptor-deficient mice. , 1998, Journal of lipid research.

[35]  A. Dembińska-kieć,et al.  Correlation of the -3826A >G polymorphism in the promoter of the uncoupling protein 1 gene with obesity and metabolic disorders in obese families from southern Poland. , 2002, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[36]  M. Walski,et al.  Ultrastructural alterations of endothelium covering advanced atherosclerotic plaque in human carotid artery visualised by scanning electron microscope. , 2002, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[37]  J. Drobnik,et al.  Response of aorta connective tissue matrix to injury caused by vassopressin-induced hypertension or hypercholesterolemia. , 2000, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[38]  N. Maeda,et al.  The two-receptor model of lipoprotein clearance: tests of the hypothesis in "knockout" mice lacking the low density lipoprotein receptor, apolipoprotein E, or both proteins. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Robert V Farese,et al.  Transgenic mice expressing high plasma concentrations of human apolipoprotein B100 and lipoprotein(a). , 1993, The Journal of clinical investigation.

[40]  A. Lusis,et al.  Genetic control of inflammatory gene induction and NF-kappa B-like transcription factor activation in response to an atherogenic diet in mice. , 1993, The Journal of clinical investigation.

[41]  R. Gerrity The role of the monocyte in atherogenesis: I. Transition of blood-borne monocytes into foam cells in fatty lesions. , 1981, The American journal of pathology.

[42]  J. Breslow,et al.  The angiotensin-II receptor antagonist, losartan, inhibits LDL lipid peroxidation and atherosclerosis in apolipoprotein E-deficient mice. , 1997, Biochemical and biophysical research communications.

[43]  R. Ross,et al.  ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[44]  E. Rubin,et al.  ApoA-I deficiency causes both hypertriglyceridemia and increased atherosclerosis in human apoB transgenic mice. , 1998, Journal of lipid research.

[45]  Gerrity Rg The role of the monocyte in atherogenesis: I. Transition of blood-borne monocytes into foam cells in fatty lesions. , 1981 .

[46]  M. Callow,et al.  Expression of human apolipoprotein B and assembly of lipoprotein(a) in transgenic mice. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[47]  E. Rubin,et al.  Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. , 1994, The Journal of clinical investigation.

[48]  R. Frants,et al.  Transgenic mice carrying the apolipoprotein E3-Leiden gene exhibit hyperlipoproteinemia. , 1993, The Journal of biological chemistry.